Our mission

Transmural Biotech develops innovative products and services in the clinical field through image analysis technologies that allow personalized, economical, non-invasive and efficient medicine.

LEADERSWe are one of the 20 most important MedTech companies in the world.

VANGUARDWe develop medical technologies based on image diagnosis through artificial intelligence. Two basic platforms: image-based AI and algorithms as a predictive basis for medical diagnosis.

COMMITTED TO MEDICINEWe are committed to a personalized, predictive, non-invasive, rapid and reliable clinical diagnosis..

INTERNATIONAL SOUL We are committed to a global distribution.

About us

Products

0

COUNTRIES
can benefit from our technology

0

CLINICS AND HOSPITALS
around the world provide our tests

+0

DIAGNOSTIC TEST
successfully performed since 2016

0%

POSITIVE EXPERIENCES
of patients who have trusted us

Last News

The advances in medical technologies of Transmural Biotech have earned a place in the media. Our belief to the medicine of the future and our commitment to science are news.

We are one of the most relevant digital companies, according to ‘The Silicon Review’

The annual ranking of one of the most prestigious magazines in the world in the biotech sector, “The Silicon Review”, included Transmural Biotech amongst the 50 top companies of 2019. This award celebrates the value and excellence of our work as well as our contribution to the technological and business market.

In the top 20 most innovative medtech companies according to “Technology Innovators”

Transmural Biotech is amongst the most innovative medical technology companies of 2019, according to the magazine “Technology Innovators”. Our focus on a personalized, preventive and non-invasive medicine through the use of state-of-the-art Artificial Intelligence techniques has been internationally recognized.

Award to the most promising innovation in Digital Medicine in 2019 for quantusFLM

We received from the American organization NODE.Health the “Most Promising Digital Medicine Innovation” award for the development of our first product, quantusFLM, during the Digital Medicine Conference 2019, in New York. They judged the test as a technological promise due to the clinical evidence and results validating it. 

They trust us

“One of the major challenges in the modern obstetrics has been to determine the Fetal Lung Maturity. But traditional methods based on amniocentesis have the limitation for being invasive and having the risk to cause premature rupture of membranes and preterm labor. quantusFLM is the solution to this clinical dilemma.”
Dr. Rogelio Cruz, Medicina Fetal México (Querétaro, Mexico)
“It is so amazing that we don’t need to analyze the amniotic fluid to determine the fetal lung maturity.”
Dr. Guillermo Azumendi, Centro Gutenberg (Málaga, Spain)
“Personalized, predictive and non-invasive medicine is the future”
Dr. Eduard Gratacós, BCNatal (Barcelona, Spain)
“quantusFLM lets us to know fetal lung maturity based on respiratory morbidity risk with a high reliability, that helps to end labor in the correct moment.”
Dr. Josué Zapata, Escuela Ecoimagen (Lima, Perú)

Our partners

Our research and development work in medical technologies would not be possible without the collaboration of some of the main hospitals, health centers and specialized research groups in Spain and Latin America. Thanks for your support!

Main partner

In collaboration with

Our partner

Our research and development work in medical technologies would not be possible without the collaboration of some of the main hospitals, health centers and specialized research groups in Spain and Latin America. Thanks for your support!

Main partner

In collaboration with

Contact us